Last updated: February 16, 2026
What Is the Current Market Status of NDC 69238-2512?
NDC 69238-2512 is identified as a topical corticosteroid cream used for dermatological conditions. It is marketed under the brand name ECZEMA RELIEF. The drug competes against a range of over-the-counter (OTC) and prescription corticosteroid creams.
In recent years, the market for dermatological corticosteroids has experienced steady growth. The global dermatology drug market was valued at approximately USD 24 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of around 6% until 2030 ([1]). Topical corticosteroids constitute roughly 30-40% of this market segment.
The product's primary markets include the United States, Canada, parts of Europe, and select Asian countries. In the U.S., the OTC segment dominates, with prescription sales occupying a smaller share.
How Is the Market for Topical Corticosteroids Positioned?
Market Share and Competition
-
NDC 69238-2512 is a non-prescription product, primarily competing with other OTC corticosteroid creams such as hydrocortisone 1% and 2%.
-
Major OTC brands include Cortizone-10 and Aveeno Eczema Therapy.
-
Prescription topical corticosteroids like clobetasol and betamethasone have higher potency and are prescribed for severe conditions, differentiating their market from OTC creams.
Pricing Dynamics
-
OTC corticosteroids typically retail between USD 8 to USD 15 for a 30g tube.
-
NDC 69238-2512 is positioned at the lower end for OTC creams, with an average retail price around USD 10.
-
Premium brands or formulations with additional benefits (e.g., moisturizing agents) can command prices up to USD 15.
Distribution Channels
-
Major channels include pharmacy chains, big-box retailers, online pharmacies, and independent drugstores.
-
Online sales of OTC corticosteroids have increased, representing approximately 20% of OTC dermatology product sales in the US in 2022 ([2]).
What Are Price Projections for NDC 69238-2512?
Short-Term (Next 1–2 Years)
-
Retail prices are expected to hover around USD 10, with minor variations based on retailer and geographic location.
-
Promotional discounts and store-brand equivalents pressure pricing, possibly reducing margins for manufacturers.
-
As OTC sales increase, price sensitivity remains high among consumers.
Medium to Long-Term (3–5 Years)
-
Prices are likely to remain stable unless new formulations with superior efficacy or safety profiles enter the market.
-
Innovations such as combination creams with antihistamines or moisturizers may demand premium pricing, pushing average prices toward USD 12–14.
-
Competition from store-brand equivalents could push prices downward by approximately 10–15%.
Influencing Factors
-
Patent expiration typically leads to increased competition, but since NDC 69238-2512 is an OTC drug, patent status has less impact on price than regulatory approvals and formulation patents.
-
Regulatory changes, such as reclassification of certain corticosteroids or new OTC monographs, could alter product positioning.
-
Price regulation policies in major markets may also influence pricing strategies.
How Does NDC 69238-2512 Compare with Similar Products?
| Product |
Type |
Potency |
Retail Price (USD) |
Market Position |
| NDC 69238-2512 (Eczema Relief) |
OTC corticosteroid |
Low |
10 |
Budget-friendly, OTC alternative |
| Cortizone-10 |
OTC corticosteroid |
Low |
8–12 |
Leading brand, low-cost option |
| Aveeno Eczema Therapy |
OTC corticosteroid |
Low |
10–15 |
Moisturizing formulation |
| Hydrocortisone 2.5% cream |
OTC corticosteroid |
Low |
8–10 |
Generic alternative |
What Are Key Market Trends and Future Opportunities?
-
Growing awareness of dermatological conditions boosts OTC corticosteroid sales.
-
Consumer preference shifts toward skin-friendly, moisturizing formulations.
-
Increasing online pharmacy penetration alters distribution and pricing dynamics.
-
Entry of natural or "clean" label products may fragment the market further.
-
Regulatory reclassification of certain corticosteroids could impact product availability and prices.
What Strategic Considerations Should Stakeholders Make?
-
For manufacturers: Formulation enhancements and combination products can justify premium pricing.
-
For retailers: Price promotions and bundling can increase sales volume.
-
For investors: The OTC segment's stability and growth amid competitive pressure suggest steady revenue streams, but innovation risk persists.
Key Takeaways
-
NDC 69238-2512 operates in a mature OTC dermatology market with high competition.
-
The average retail price remains around USD 10 with minor fluctuations.
-
Market growth is driven by increasing dermatological conditions, consumer awareness, and online sales.
-
Price competition from generics and store brands influences margins.
-
Future opportunities focus on formulation innovation and digital distribution channels.
FAQs
1. How does patent expiration affect OTC corticosteroid prices?
Patents have limited influence on OTC drugs, as formulations are often protected by regulatory exclusivities and branding. However, generic and store-brand competitors exert downward pressure regardless.
2. Are there upcoming regulatory changes expected to impact this product?
Potential reclassification of certain corticosteroids or updates to OTC monographs could alter product availability or labeling, affecting pricing and market share.
3. What is the typical profit margin for OTC corticosteroid creams?
Margins vary but generally range from 15% to 25%, influenced by manufacturing costs, retailer discounts, and competitive pricing.
4. Could new formulations replace NDC 69238-2512 in the market?
Yes, if new formulations offer better safety, efficacy, or consumer appeal, they can supplant existing products, especially with increasing innovation in skin care.
5. How significant is the online market for OTC dermatological products?
Online sales constitute around 20% of OTC dermatology product sales in the US, with growth driven by convenience and direct-to-consumer marketing.
References
[1] MarketsandMarkets, "Dermatology Drugs Market," 2022.
[2] IQVIA, "US Over-the-Counter Medication Sales Data," 2022.
